
US pharma giant Pfizer (NYSE: PFE) today reported fourth-quarter 2014 earnings of $1.23 billion, and net earnings per share of $0.91, a slump of 51%. Pfizer’s shares dipped 0.9% to $32.80 in pre-market trading this morning, but were up 0.32% to $32.90 at 9:46 am.
Earnings, adjusted for non-recurring costs and costs related to mergers and acquisitions were $0.54 per share, beating Wall Street expectations and just shy of Zacks Investment Research’s forecast of $0.53. Pfizer posted revenue of $13.12 billion in the period, down 3%, but also topping Wall Street forecasts if $12.87 billion, according to Zacks.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze